Persistent back pain is easy to blame on a bad mattress, poor posture, an ambitious workout, or the increasingly creative positions people use while staring at a phone. Sometimes, however, the problem is not mechanical strain. It is inflammation.
Non-radiographic axial spondyloarthritis, commonly abbreviated as nr-axSpA, is a chronic inflammatory arthritis that primarily affects the sacroiliac joints and spine. Unlike radiographic axial spondyloarthritis, its characteristic structural damage is not clearly visible on standard X-rays. That does not make the pain imaginary, minor, or “too early to count.” It simply means the disease cannot be defined by conventional X-ray changes.
Understanding the symptoms, testing process, and treatment options can shorten the frustrating journey from “your X-ray looks normal” to a management plan that actually addresses the inflammation.
What Is Non-Radiographic Axial Spondyloarthritis?
Axial spondyloarthritis, or axSpA, is a family of inflammatory diseases centered on the body’s axial skeleton. This includes the spine and the sacroiliac joints, which connect the lower spine to the pelvis.
The condition is generally divided into two forms:
- Non-radiographic axial spondyloarthritis: Symptoms and clinical evidence suggest axSpA, but definite structural sacroiliac-joint damage is not visible on conventional X-rays.
- Radiographic axial spondyloarthritis: Structural changes are visible on X-rays. This form has traditionally been called ankylosing spondylitis.
The word “non-radiographic” can be misleading. It does not mean that every imaging test is normal. An MRI may detect active inflammation or structural lesions that an X-ray misses. Some people also have convincing clinical features despite an MRI that does not show clear inflammation.
Nr-axSpA is not automatically a mild version of ankylosing spondylitis. People in both groups can experience substantial pain, fatigue, sleep disruption, reduced mobility, and difficulty working. It is also not necessarily a temporary stage. Some patients eventually develop X-ray changes, while many never progress to radiographic disease.
Common Symptoms of Nr-axSpA
Inflammatory Back Pain
The most recognizable symptom is chronic lower-back or buttock pain with an inflammatory pattern. It often begins before age 45 and lasts longer than three months.
Inflammatory back pain tends to:
- Develop gradually rather than after one memorable injury
- Feel worse after resting or sitting for long periods
- Cause significant morning stiffness
- Improve with movement or exercise
- Wake a person during the second half of the night
- Cause pain that alternates between the left and right buttocks
That movement-related improvement is an important clue. Mechanical back pain often asks for a couch. Inflammatory back pain may treat the couch as a personal enemy.
Fatigue
Fatigue in nr-axSpA can feel more intense than ordinary sleepiness. Chronic inflammation, pain, interrupted sleep, medication effects, stress, and reduced physical activity may all contribute. A person may technically sleep eight hours and still wake up feeling as though the night shift forgot to clock out.
Enthesitis
Enthesitis is inflammation where tendons or ligaments attach to bone. Common locations include the heels, bottoms of the feet, ribs, hips, knees, and elbows. Achilles tendon or plantar fascia pain can make the first steps of the morning especially unpleasant.
Peripheral Joint Symptoms
Although “axial” refers to the spine and pelvis, nr-axSpA can affect joints elsewhere. The hips, knees, ankles, and shoulders may become painful, stiff, or swollen. Some people also develop dactylitis, a sausage-like swelling of an entire finger or toe.
Symptoms Outside the Joints
Axial spondyloarthritis can involve several organ systems. Associated conditions include:
- Acute anterior uveitis: Sudden eye pain, redness, blurred vision, and sensitivity to light
- Psoriasis: Inflamed, scaly skin patches or changes in the fingernails and toenails
- Inflammatory bowel disease: Crohn’s disease or ulcerative colitis
- Reduced chest expansion: Pain or stiffness around the ribs can make deep breathing uncomfortable
Sudden eye pain or light sensitivity requires prompt medical attention. Uveitis is not a “wait until next month’s appointment” situation.
What Causes Non-Radiographic Axial Spondyloarthritis?
There is no single known cause. Nr-axSpA appears to develop through a combination of genetic susceptibility, immune-system activity, and environmental influences.
The Role of HLA-B27
HLA-B27 is a genetic marker strongly associated with axial spondyloarthritis. However, it is not a diagnosis by itself. Many people who carry HLA-B27 never develop the disease, and some patients with confirmed nr-axSpA test negative for it.
The frequency of HLA-B27 varies across racial and ethnic populations. A clinician must therefore interpret the result alongside symptoms, examination findings, imaging, family history, and laboratory tests.
Family History
Having a close relative with ankylosing spondylitis, nr-axSpA, psoriasis, uveitis, or inflammatory bowel disease may increase suspicion. Family history is useful evidence, but the disease is not inherited through a simple one-gene guarantee.
Immune-System Inflammation
Inflammatory pathways involving tumor necrosis factor and interleukin-17 contribute to axSpA. These pathways help explain why medications targeting TNF or IL-17 can reduce disease activity in appropriately selected patients.
Why Diagnosis Can Take So Long
Back pain is extremely common, while nr-axSpA is comparatively uncommon and has no single definitive test. Early symptoms may resemble muscle strain, degenerative disc disease, fibromyalgia, sciatica, hypermobility, or ordinary nonspecific back pain.
Patients may also be reassured by a normal X-ray even though normal radiographs are part of the definition of nr-axSpA. Women have historically faced additional diagnostic delays, partly because axial spondyloarthritis was once incorrectly viewed as a disease affecting mainly men. Women may also have less obvious X-ray progression and more widespread pain or enthesitis.
A rheumatologist usually makes the diagnosis by assembling several pieces of evidence rather than waiting for one test to arrive wearing a superhero cape.
Medical History and Physical Examination
The clinician will ask when the pain began, whether it improves with activity, how long morning stiffness lasts, and whether symptoms disturb sleep. Questions about psoriasis, bowel problems, eye inflammation, heel pain, previous infections, family history, and responses to anti-inflammatory medication are also relevant.
The physical examination may evaluate spinal mobility, hip movement, chest expansion, tender tendon attachments, swollen joints, skin, nails, and areas around the sacroiliac joints.
X-Rays and MRI
Pelvic X-rays help identify structural changes in the sacroiliac joints. When those changes do not meet the threshold for radiographic axSpA, MRI may be used to look for active inflammation, erosions, fatty changes, or other lesions.
MRI is valuable, but it is not a magical truth machine. Bone-marrow edema resembling sacroiliitis can appear after intense physical activity, during or after pregnancy, with mechanical stress, and occasionally in healthy people. Images must be interpreted in the context of the entire clinical picture.
Blood Tests
Testing may include:
- C-reactive protein and erythrocyte sedimentation rate: Markers that may rise with inflammation
- HLA-B27 testing: A genetic clue that can increase or decrease diagnostic probability
- Additional testing: Used when another inflammatory, infectious, or metabolic condition is possible
Normal inflammatory markers do not rule out nr-axSpA. Plenty of patients have active symptoms without an elevated CRP or ESR.
Classification Criteria Are Not a Stand-Alone Diagnosis
Research classification criteria help create consistent groups for clinical studies. They can support clinical thinking, but they should not be treated as an automatic diagnostic checklist. Diagnosis requires professional judgment and careful exclusion of alternative explanations.
How Nr-axSpA Is Treated
Treatment aims to reduce inflammation, control pain and stiffness, preserve mobility, improve sleep and function, and address related conditions. The plan should reflect disease activity, other health conditions, personal preferences, medication risks, and practical issues such as cost and insurance coverage.
Exercise and Physical Therapy
Regular exercise is a core treatment rather than a decorative lifestyle suggestion. A physical therapist familiar with inflammatory arthritis can design a program involving:
- Spinal and hip mobility exercises
- Posture training
- Strengthening
- Aerobic conditioning
- Chest-expansion and breathing exercises
- Strategies for safely modifying activity during flares
Consistency matters more than turning every session into an audition for an action movie. Short daily mobility work may be more sustainable than one heroic workout followed by four days of regret.
Nonsteroidal Anti-Inflammatory Drugs
NSAIDs are commonly used as initial medication treatment when they are medically appropriate. They may reduce pain, morning stiffness, and inflammation. Because they can affect the stomach, kidneys, blood pressure, heart, and interactions with other medicines, the safest drug and dose should be discussed with a healthcare professional.
Conventional DMARDs
Traditional disease-modifying antirheumatic drugs such as sulfasalazine generally do not work well for symptoms centered in the spine. They may be considered when peripheral joints are significantly involved.
Long-term systemic corticosteroids are generally avoided for axial disease because their risks usually outweigh limited long-term benefit. Local injections may occasionally be used for selected peripheral joints or inflamed tendon-attachment areas.
Biologic and Targeted Therapies
When active disease continues despite exercise, physical therapy, and appropriate NSAID treatment, advanced therapy may be considered. Current treatment options include TNF inhibitors, IL-17 inhibitors, and, for selected patients, JAK inhibitors.
Examples with FDA-approved nr-axSpA indications include certolizumab pegol, ixekizumab, secukinumab, and upadacitinib. Indications differ, and some require objective evidence of inflammation or an inadequate response to previous treatment.
Current American College of Rheumatology guidance supports TNF inhibitors and IL-17 inhibitors as preferred initial advanced-treatment classes for many adults with active axial spondyloarthritis. JAK inhibitors may be appropriate in certain circumstances but are not generally positioned as the first advanced therapy for everyone.
Associated conditions can influence the choice. A monoclonal TNF inhibitor may be favored when recurrent uveitis or active inflammatory bowel disease is present, while an IL-17 inhibitor may be particularly useful when significant psoriasis is part of the picture.
Advanced therapies suppress specific immune pathways and can increase infection risks. Screening for tuberculosis, reviewing vaccination status, checking relevant laboratory tests, and discussing pregnancy plans or other medical conditions are important before treatment.
Everyday Management Strategies
- Break up sitting time: Stand, stretch, or walk briefly throughout the day.
- Track patterns: Record morning stiffness, night waking, fatigue, medication use, and activity tolerance.
- Use heat thoughtfully: Warm showers or heating pads may relax stiff muscles and joints.
- Protect sleep: Address nighttime pain, sleep position, stress, and possible sleep disorders.
- Stop smoking: Smoking is associated with worse disease outcomes and adds cardiovascular and breathing risks.
- Eat for overall health: No special diet cures nr-axSpA, but a balanced eating pattern supports cardiovascular, metabolic, and bone health.
- Coordinate care: Eye, skin, or bowel symptoms may require collaboration among rheumatology, ophthalmology, dermatology, and gastroenterology.
Symptoms alone do not always reveal how much inflammation is present. Follow-up visits may include disease-activity scores, examination findings, laboratory monitoring, and discussions about function, work, sleep, and treatment side effects.
Does Nr-axSpA Always Progress to Ankylosing Spondylitis?
No. Progression rates vary considerably across studies, and many people never develop definite X-ray changes. Higher CRP levels, substantial inflammation on MRI, smoking, and male sex have been associated with a greater probability of radiographic progression in some research.
Not progressing on X-ray does not necessarily mean the disease has disappeared. A person can continue to experience active inflammation and meaningful symptoms while remaining in the non-radiographic category.
With individualized treatment, many patients can reduce disease activity, maintain mobility, continue working, exercise, travel, and participate in family life. Remission or low disease activity is possible, although flares may still occur.
When to Seek Medical Care
Consider discussing a rheumatology evaluation when back pain begins before age 45, persists for more than three months, improves with movement, worsens with rest, or occurs with psoriasis, uveitis, inflammatory bowel disease, heel pain, or a family history of spondyloarthritis.
Seek urgent medical attention for sudden eye pain or vision changes, new weakness or numbness, loss of bladder or bowel control, severe chest symptoms, high fever, or signs of serious infectionparticularly while taking immune-modifying medication.
A Composite Experience of Living With Nr-axSpA
The following story is a fictionalized composite based on commonly reported patient experiences. It does not describe one identifiable person and should not be interpreted as medical advice.
Jordan first noticed the back pain at 29. It was not dramatic. There was no fall, no lifting accident, and no cinematic moment involving a suspiciously heavy cardboard box. The lower back simply became stiff in the mornings.
At first, Jordan blamed an office chair. A new chair arrived with adjustable lumbar support, adjustable armrests, and enough levers to operate a small aircraft. The pain continued.
Over the next two years, the stiffness began lasting more than an hour. Sleeping late on weekends made it worse, while walking around the neighborhood made it better. Some nights, pain deep in one buttock caused Jordan to wake up and pace through the kitchen. Oddly, movement at 3 a.m. helped more than lying still.
A primary care visit led to advice about stretching and core strength. Physical therapy helped somewhat, but the symptoms kept returning. An X-ray was normal, which sounded reassuring but did not explain why putting on socks had become a morning engineering project.
Then came heel pain. After that, one eye became red, painful, and extremely sensitive to light. An ophthalmologist diagnosed acute anterior uveitis and asked about back stiffness. That connection eventually led to a rheumatology referral.
The rheumatologist did not diagnose nr-axSpA from a single clue. Jordan’s gradual back pain, prolonged morning stiffness, improvement with exercise, nighttime symptoms, uveitis, examination findings, and family history all mattered. Blood tests showed HLA-B27 positivity, but inflammatory markers were normal. An MRI revealed inflammation around the sacroiliac joints even though the X-ray still showed no definite structural damage.
Receiving the diagnosis brought mixed emotions. There was relief that the symptoms had a name and frustration that it had taken years to find it. The phrase “non-radiographic” initially sounded like “nothing is wrong,” until the rheumatologist explained that the term described the X-raynot the severity or legitimacy of the illness.
Treatment began with a structured exercise plan, physical therapy, and an NSAID selected after reviewing Jordan’s medical history. Morning mobility exercises became part of the routine. Some days, ten minutes was enough. On other days, the yoga mat remained on the floor mostly as a strongly worded suggestion.
Symptoms improved but remained active. After several months and a shared discussion about benefits, risks, uveitis history, insurance requirements, and infection screening, Jordan started advanced therapy. Improvement was gradual rather than magical. Morning stiffness shortened, nighttime waking became less frequent, and weekend plans no longer had to be negotiated with the lower back several days in advance.
There were still flares. Long flights, stressful workweeks, poor sleep, and skipped exercise occasionally created a perfect storm. Jordan learned to request an aisle seat, stand during long meetings, schedule movement breaks, and explain the condition without apologizing for it.
The most useful lesson was that managing nr-axSpA was not about pretending pain did not exist or treating the body like fragile glass. It was about combining medical care, movement, pacing, monitoring, and communication. The diagnosis did not make Jordan’s life smaller. It provided a better map for navigating it.
Conclusion
Non-radiographic axial spondyloarthritis is a real inflammatory disease even when standard X-rays do not reveal definite sacroiliac-joint damage. Its hallmark features include chronic inflammatory back pain, morning stiffness, improvement with movement, fatigue, enthesitis, and possible eye, skin, or bowel involvement.
Diagnosis requires a complete clinical assessment rather than dependence on one scan, one blood marker, or one classification checklist. Treatment commonly combines regular exercise, physical therapy, appropriate anti-inflammatory medication, and advanced immune-targeting therapy when disease remains active.
Recognizing the pattern matters. A normal X-ray should not automatically end the investigation when symptoms strongly suggest inflammatory back disease. Earlier rheumatology evaluation can lead to better symptom control, preserved mobility, and fewer years spent arguing with a supposedly innocent mattress.
Research synthesis included guidance and educational material from the American College of Rheumatology, Spondylitis Association of America, Arthritis Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Mayo Clinic, FDA prescribing information, and peer-reviewed medical literature.
Current U.S. medication indications were cross-checked against FDA prescribing information.
